Ongoing HTAs in Norway in March 2024

In March 2024, several method assessments were initiated as a part of a framework for the managed introduction of innovations "New Methods" for cardiovascular, endocrine, gastrointestinal, men’s health, neurology and neurosurgery, neuromodulation, obstetrics and gynecology, robotic surgery, and some other fields. Some examples are listed below: 

• Pacemaker without lead for the treatment of atrial fibrillation and bradycardia – Reassessment;
• Wearable cardioverter defibrillator for people at high risk of sudden cardiac arrest;
• Continuous glucose measurement and flash glucose measurement in diabetes type II;
• Robot-assisted surgery for prostatectomy;
• Robot-assisted surgery for proctectomy;
• Robot-assisted surgery for hysterectomy;
• Magnetic resonance (MR)-guided high-intensity focused ultrasound for the treatment of essential tremor, Parkinson's disease and neuropathic pain;
• Electric field therapy (Optune, Tumor-Treating Fields).

The full details in Norwegian can be found here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.